All In Biotech

Drug Trial Radar · NCT07943078

A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 Trial of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Jan 5, 2029

Study completion Jan 16, 2030

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out how safe and well-tolerated JNJ-99220732 is and to find out the most suitable dose (\[putative\] recommended phase 2 dose \[pRP2D\] regimen\[s\]) of JNJ-99220732 (Part 1-Dose Escalation). Also, to find out how safe and well-tolerated JNJ-99220732 is at the pRP2D regimen(s) as determined in Part 1 (Part 2- Dose Expansion).

Conditions

  • Neoplasms

Interventions

  • JNJ-99220732Drug

    JNJ-99220732 will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE) by SeverityTime frame: Up to 3 years 2 months
  2. Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 21 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.